# LAM561 With RT and TMZ for Adults With Glioblastoma

> **NCT04250922** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Laminar Pharmaceuticals** · enrollment: 144 (actual)

## Conditions studied

- Primary Glioblastoma
- Glioblastoma Multiforme

## Interventions

- **DRUG:** LAM561
- **DRUG:** TMZ
- **RADIATION:** RT

## Key facts

- **NCT ID:** NCT04250922
- **Lead sponsor:** Laminar Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-01
- **Primary completion:** 2026-01-15
- **Final completion:** 2026-11-30
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2025-11-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04250922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04250922, "LAM561 With RT and TMZ for Adults With Glioblastoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04250922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*